Safety, Pharmacokinetics, and Functional Activity of Human Anti-Pseudomonas aeruginosa Monoclonal Antibodies in Septic and Nonseptic Patients
- 1 October 1991
- journal article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 164 (4) , 803-806
- https://doi.org/10.1093/infdis/164.4.803
Abstract
A mixture of five IgM human monoclonal antibodies (MAbs) against lipopolysaccharide antigens of Pseudomonas aeruginosa, plus a human IgG 1 MAb against exotoxin A, were studied in 12 noninfected patients and 8 patients with P. aeruginosa bacteremia or pneumonia (or both). The preparation was well tolerated over a dose range of 0.3–1.2 mllkg (0.75–3.0 mg/kg IgM protein). After a single infusion of 1.2 ml/kg (3.0 mg/kg IgM protein), serum antibody titers were boosted into therapeutic range, with serum half-lives ranging from 34 to 99 h. Also, opsonophagocytic activity in serum rose more than 1 log10 for all but one antibody. In no patient was an immunologic response against the MAb preparation detected.Keywords
This publication has 0 references indexed in Scilit: